Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study - 01/02/21
Doi : 10.1016/j.jaci.2020.12.524
Kim Paes 1 : Clinical Scientist, Jonathan Bernstein, MD FAAAAI 2, Hilary Longhurst, PhD MBBS MRCP FRCP 3, Emel Aygoren-Pursun, MD 4, Hong Ren, MS 5, Timothy Craig, DO FAAAAI 6
1 Takeda Pharmaceutical Company Limited, Lexington, MA, USA
2 Department of Internal Medicine, Division of Immunology, University of Cincinnati College of Medicine, Bernstein Allergy Group and Bernstein Clinical Research Center, Cincinnati, OH, USA
3 Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, and University College London Hospitals, London, UK
4 Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
5 Cytel Inc., Cambridge, MA, USA
6 Department of Medicine, Pediatrics and Graduate Studies, Penn State University Hershey Medical Center, Hershey, PA, USA
462
Le texte complet de cet article est disponible en PDF.Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB145 - février 2021 Retour au numéro
Article précédent
- Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Allergic Rhinitis
- Lisa Beck, Andreas Wollenberg, Amy Paller, Elaine Siegfried, Zhen Chen, Alvina Abramova, Randy Prescilla
- Pregnancy and infant outcomes among pregnant women with Chronic Spontaneous Urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry
- Jennifer Namazy, Angela Scheuerle, Vic Spain, Pranathi Janampally, Ayesha Ahmed, Sachin Gupta, Cecile Holweg, Nayla Mumneh, Cristine Radojicic
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?